Clinical trials of the drug have shown mixed results.
Academic rigor, journalistic flair
Articles on beta amyloid plaques
Displaying all articles
The first drug targeting Alzheimer’s disease has been approved in 20 years – but its approval isn’t based on substantial evidence.
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
Trials for new Alzheimer’s drugs have been failing a lot, lately. But it may be premature to abandon these drugs altogether.
A lot of Alzheimer’s treatments focus on removing plaques in the brain. But could this be the wrong target?
The first clinical trial examining a drug to treat Alzheimer’s was begun 30 years ago. There is still no cure and no known way to prevent the disease. Two factors may contribute to that.
Researchers have found evidence of the same brain pathologies in dolphins that are present in the brains of humans who died with Alzheimer’s. What might this suggest about Alzheimer’s in humans?
Top contributors
-
Postdoctoral Researcher in Neuroscience, University of Sussex
-
Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut
-
Director, Evelyn F. and William L. McKnight Brain Institute Director, 1Florida Alzheimer’s Disease Research Center, Professor, Department of Neuroscience, College of Medicine University of Florida, University of Florida
-
Assistant Scientist, University of Florida
-
Professor, Neuroscience, University of Florida
-
PhD Candidate, University of Sussex
-
Liverpool John Moores University
-
Professor and Chair in Ageing and Alzheimer’s Disease, Edith Cowan University
-
Research Associate in Neuroimmunology, Cardiff University
-
PhD Candidate, Neuroscience, Cardiff University
